RPA3

Across TCGA pan-cancer cohorts, RPA3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPA3 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RPA3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPA3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

UCEC, LUAD, and CCRCC are the cancer types where RPA3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Tertile	II,III,IV	0.497	1.000	.014	26	view →
LUAD	DFS	Median	All	0.893	0.487	.002	23	view →
CCRCC	DFS	Median	III,IV	0.880	0.487	<.001	19	view →
LSCC	OS	Tertile	II,III,IV	0.950	0.702	.028	4	view →
PDAC	DFS	Tertile	All	0.478	0.313	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPA3–UCEC (OS)

Open the UCEC breakdown →